Drug Trial Radar · NCT03416179
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
730
Actual
Start
Apr 20, 2018
Primary completion
Jun 5, 2020
Study completion Jan 17, 2022
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).
Conditions
- Leukemia, Myeloid, Acute
Interventions
glasdegibDrug
Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first. Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
daunorubicin + cytarabineDrug
'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days). If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');
azacitidineDrug
Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
PlaceboDrug
Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first. Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
PlaceboDrug
Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
glasdegibDrug
Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
cytarabineDrug
Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
HSCTProcedure
If required, and done per standard of care post Induction(s).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intensive Study: Overall Survival (OS)Time frame: Baseline up to 25 months
- Non-intensive Study: Overall Survival (OS)Time frame: Baseline up to 25 months
Locations
149 sites in 22 countries. Site status is shown where the registry gives one.
UCLA Department of Medicine
Los Angeles, California
UCLA Drug Information/Investigational Drugs
Los Angeles, California
UCLA Hematology/Oncology Clinic
Los Angeles, California
UCLA Ronald Reagan Medical Center
Los Angeles, California
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
University of California, San Francisco
San Francisco, California
UCLA Hematology/Oncology - Westlake Village
Westlake Village, California
Augusta University Medical Center
Augusta, Georgia
Georgia Cancer Center at Augusta University
Augusta, Georgia
Tufts Medical Center Investigational Drug Pharmacy
Boston, Massachusetts
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
MidAmerica Division, Inc., c/o Research Medical Center
Kansas City, Missouri
Northwell Health/Monter Cancer Center
Lake Success, New York
North Shore University Hospital
Manhasset, New York
Long Island Jewish Medical Center
New Hyde Park, New York
University of Rochester Medical Center
Rochester, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
OHSU Center for Health and Healing
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Centennial Medical Center
Nashville, Tennessee
TriStar Bone Marrow Transplant
Nashville, Tennessee
Baylor University Medical Center
Dallas, Texas
Blood Cancer and Stem Cell Transplant Clinic
San Antonio, Texas
Methodist Healthcare System of San Antonio
San Antonio, Texas
Swedish Cancer Institute
Seattle, Washington
Swedish Medical Center
Seattle, Washington
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU
Salzburg, Austria
Uniklinikum Salzburg, Landeskrankenhaus Salzburg
Salzburg, Austria
Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel
Vienna, Austria
AZ Sint-Jan Brugge-Oostende av
Bruges, Belgium
Universitaire Ziekenhuizen Brussel (UZ Brussel)
Brussels, Belgium
Universitaire Ziekenhuizen Brussel
Brussels, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.